Ibogaine Documentary · Evidence record
A dated working record of clinical trials, preclinical studies, and regulatory milestones involving ibogaine, noribogaine, and DMX-1001—built to keep emerging evidence separate from conclusions it cannot yet support.
This page is for research context, not diagnosis, treatment selection, or medical advice.
Reading the record
Entries are included when a study or milestone has an identifiable primary source: a trial registry record, peer-reviewed paper, preprint, sponsor communication, or official regulatory material. The tracker prioritizes work from 2020 onward and distinguishes human research from laboratory and animal work.
Each entry names the design, stated primary outcome measures, sponsor, and recorded recruitment status. Registry terminology is retained when possible because a status field can change before results appear. For broader orientation, the ibogaine documentary resource places these records alongside questions of evidence, culture, and safety.
Clinical record
Clinical trial registries describe protocols and planned measures; they are not proof of a result. The U.S. ClinicalTrials.gov registry is a useful primary record for checking a study’s stated design and recruitment field.
Public records for ibogaine-related human research vary substantially in design, setting, eligibility criteria, monitoring, and outcome definitions. A current registry entry is the appropriate starting point for checking whether a study is recruiting, active, completed, withdrawn, or has posted results.
Search the current ibogaine study records rather than inferring status from summaries or promotional language.
Noribogaine is an active metabolite associated with ibogaine, and DMX-1001 has been publicly described as a noribogaine development program. Public sponsor materials should be read as program updates, while the corresponding registry record or published paper remains the best source for details of design, endpoints, and participant status.
The atai Life Sciences public company materials provide an official starting point for sponsor communications, but they do not substitute for independently assessable study results.
Ibogaine has known safety concerns, including cardiac risk, which makes protocol details and exclusion criteria essential rather than incidental. The U.S. FDA safety communication on ibogaine-related risk is relevant context for interpreting why monitored research settings document screening and adverse events.
Preclinical & translational work
Laboratory and animal studies can help frame mechanisms, metabolites, dose questions, and hypotheses for later work. They cannot establish effectiveness or safety in people.
Published work may examine the parent compound, its metabolite, receptor activity, toxicity questions, or formulation approaches. The ibogaine reference overview can help orient a reader to terminology, but original studies are needed for claims about any specific finding.
Preclinical entries are interpreted through their reported model, comparison, timing, and measured endpoint. A finding in one model does not automatically transfer to another model, a clinical setting, or an individual decision.
Names such as DMX-1001 identify a program, not a settled clinical conclusion. This tracker treats sponsor statements, registry updates, and peer-reviewed publications as separate source types and notes uncertainty where the public record is incomplete.
Regulatory milestones
Regulatory status is jurisdiction-specific and can concern a substance, an investigational program, a study authorization, or a separate access framework. A record of development activity does not equal approval, and a research designation does not answer questions about clinical availability.
For a plain-language frame on how studies are assessed, the FDA’s drug development and approval process describes the distinct steps between research and marketing authorization. Those distinctions matter when evaluating public discussion of ibogaine or noribogaine.
Questions that connect evidence with practical risk are gathered in Root Meridian’s discussion of ibogaine duration, where timing is treated as a context question rather than a prediction for any person.
“Status,” “completion,” and “results” are different fields—and each deserves its own source.
Tracker principle
Practical questions
Use the original record to test a claim, and keep the limits of that record in view.
It follows identifiable clinical trials, preclinical research, peer-reviewed papers, registry records, and regulatory milestones involving ibogaine, noribogaine, and DMX-1001. Evidence concerning ibogaine treatment for alcohol should be read against the specific study population and outcome measure, not generalized beyond them.
Trial registries are updated by study sponsors and investigators. A record can change before results are published, so status is presented as a time-bound registry field rather than a conclusion. The same care is warranted when reviewing material about ibogaine treatment for veterans, where population-specific context matters.
No. Early-stage and observational findings may inform further research, but they do not by themselves establish effectiveness, safety, or suitability for any individual. Root Meridian’s safety and access context addresses why evidence, screening, and legal conditions should not be collapsed into one claim.
Keep the record in view
Return to the primary source, note its date and limits, and separate a research milestone from a personal recommendation.